Defining Biopharma Dealmaking Success: An Analysis Of 2003 Alliances
Executive Summary
This article examines the question do external biopharma programs succeed at similar rates as internal projects? IN VIVO examined this question by analyzing the alliances of 2003, mining both Elsevier's Strategic Transactions database and SEC documents, and bolstering these data with independent reporting.
You may also be interested in...
Abbott Becomes Third US TAVR Competitor With Portico Approval
Portico with the FlexNav delivery system earned FDA approval for people with symptomatic, severe aortic stenosis who would be at high or extreme risk in open-heart surgery.
Coronavirus Update: Pfizer/BioNTech Vaccine Shows Antibody Response In Young Kids
The companies announced data from their Phase II/III study in children aged 5-11 and intend to take them to regulators to expand Comirnaty's authorization; also, an expert panel advising India's drug regulator endorsed plans for a Phase III trial of a single-dose Russian vaccine, Sputnik Light.
Back to The Past: The Case for Improving Upon, Not Throwing Out Traditional Cancer Phase I Study Designs
US FDA has pushed sponsors away from the traditional dose-finding designs for cancer drugs in recent years. But academics continue to make a case for keeping the 3+3 design with some improvements.